New business-to-business initiative seeks to drive accessibility into procurement processes for companies that buy and sell technology and other products and services
ALEXANDRIA, Va., September 07, 2022–(BUSINESS WIRE)–Disability:IN, the global nonprofit driving disability inclusion in business, today announced the first 20 companies to sign the Procure Access Statement and join the Procure Access initiative, which encourages companies to buy and sell technology and other products and services that are accessible, usable and inclusive to people with disabilities.
The companies are AT&T, Booz Allen Hamilton, CVS Health, EY, Fable, Fidelity Investments, Google, International Flavors and Fragrances, Intel, Merck, Microsoft, Pearson, Protiviti, Robert Half, Salesforce, T-Mobile, Twitter, United Natural Foods, Vispero and Yahoo!.
Procure Access aims to help businesses understand that accessible procurement creates an inclusive workplace, marketplace and supply chain with better, more usable products and services for their employees, customers and the public. Signing the statement marks a company’s public commitment to influencing accessibility in the procurement process and collaborating with others to foster a more inclusive digital environment for everyone.
"More than 32 years after the Americans with Disabilities Act, there is still a lack of accessibility in technology and other products and services, which continues to create barriers for people with disabilities in employment and society," says Jeff Wissel, Chief Accessibility Officer of Disability:IN. "We’re excited about the awareness that Procure Access will bring to companies around the world. This is a crucial step in building a disability-inclusive workforce, customer base and supply chain."
The initial 20 signatories and future members of the Procure Access initiative will work collaboratively to identify the obstacles facing technology buyers and sellers and promote the sharing of transparent, current and accurate information about accessibility gaps and roadmaps. The focus on accessibility starts from the day products and services are being considered and continues through the selection process and the contract lifecycle.
"At Twitter, we’re on a journey to become the world’s most inclusive, diverse, equitable, and accessible tech company," says Gurpreet Kaur, Global Head of Accessibility at Twitter. "We’re proud to sign the Procure Access Statement to encourage others to take steps toward creating a more inclusive environment featuring accessible products and services for employees, customers, and the public."
"As business becomes increasingly digital, it’s critical that everyone is able to access the digital tools and content they need to work efficiently and effectively," said Hank Prybylski, EY Global Vice Chair – Transformation. "The Procure Access initiative will help expand access and create a better and more equitable working world."
Disability:IN and Procure Access participants have developed free accessible procurement resources including the Building Blocks of an Accessible Procurement Program, the Accessible Technology Procurement Toolkit and the Accessible Procurement Questions.
To read the Procure Access Statement and learn more, visit the Procure Access page on the Disability:IN website.
About Disability:IN®
Disability:IN is a global organization driving disability inclusion and equality in business. More than four hundred corporations partner with Disability:IN to create long-term business and social impact through the world’s most comprehensive disability inclusion benchmarking and reporting tool, the Disability Equality Index (DEI); best-in-class conferences and programs; expert counsel and engagement; and public policy leadership. Join us at disabilityin.org #AreYouIN.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005438/en/
Contacts
Media:
Suzanne Robitaille
Archie Group
suzanne@archiegroup.com
203-832-4107
AstraZeneca Rare Disease, the local division formed when the British pharma giant acquired Alexion Pharmaceuticals Inc. last year, has scooped up a struggling local biotech at a significant premium. AstraZeneca plc (Nasdaq: AZN) is buying LogicBio Therapeutics Inc. (Nasdaq: LOGC) for $2.07 per share, a 660% premium that values the total acquisition at $68 million. Lexington-based LogicBio has been struggling since February, when the U.S. Food and Drug Administration ordered a halt to an early-stage trial testing a drug in pediatric patients with methylmalonic acidemia, a disorder in which the body cannot break down certain proteins and fats.
Clovis Oncology Inc (NASDAQ: CLVS) announced topline data from the Phase 3 TRITON3 trial, demonstrating that Rubraca monotherapy treatment significantly improved radiographic progression-free survival (rPFS) compared with the control group. The control group consisted of the physician's choice of docetaxel, abiraterone acetate, or enzalutamide. The safety profile of Rubraca observed in the TRITON3 study was consistent with Rubraca labeling. Related: FDA's Recommendation Before Clovis Submits Rub
The stock market is often a game in reverse psychology. That is, when the mood gets too euphoric, it’s often a sign it is time to sell. Likewise, when sentiment hits the skids, that could be the ultimate signal the time is right to load up the truck. And on that subject, J.P. Morgan’s Marko Kolanovic thinks we are at – or at least near – the bottom. The firm’s global market strategist believes the Fed’s hawkish stance has left stocks “very oversold,” and while inflation remains persistently high
Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases.
Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
Is Pfizer stock a sell on an expected decline for Covid vaccine sales in the third quarter? Is PFE stock now a sell?
Amylyx Pharmaceuticals' co-founders have said they want to use their newfound platform to bring down barriers to ALS care.
Wilmington biotech company Incyte has agreed to acquire Villaris Therapeutics in a deal valued at up to $1.36 billion. The centerpiece of the deal is auremolimab, a monoclonal antibody that is under development to treat the skin disorder vitiligo — but has potential applications beyond dermatology. Villaris, based in Cary, North Carolina, was founded in 2019 and is backed by Medicxi, a health care-focused investment firm based in London.
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.
The vegetable was shown to lower blood sugar levels and cholesterol levels
Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.
Reports show that Hispanic Americans are 1.5 times more likely to be diagnosed with Alzheimer's disease than white Americans
There have long been rumors that tomatoes can trigger inflammation in the body, leading to arthritis. But is this actually true? Here's what a doctor says.
The condition is as common as it is embarrassing—but it’s not something you have to live with indefinitely.
On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.
KPIX 5's Ryan Yamamoto chats with Dr. Neha Narula from Stanford Health Care about a new experimental drug showing promising results in slowing the fatal disease that impacts more than 6 million Americans.
While largely a bill intended to combat climate change, the Inflation Reduction Act instituted several big changes for Medicare.
While there's no shortage of pundits, politicians and other prognosticators clamoring to declare the end of the pandemic, the ultimate call is up to the World Health Organization.